WO2008045970A2 - Compositions and methods of using chondroitinase abci mutants - Google Patents
Compositions and methods of using chondroitinase abci mutants Download PDFInfo
- Publication number
- WO2008045970A2 WO2008045970A2 PCT/US2007/081001 US2007081001W WO2008045970A2 WO 2008045970 A2 WO2008045970 A2 WO 2008045970A2 US 2007081001 W US2007081001 W US 2007081001W WO 2008045970 A2 WO2008045970 A2 WO 2008045970A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- enzyme
- cells
- chondroitinase
- administered
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/51—Lyases (4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/0202—Chondroitin-sulfate-ABC endolyase (4.2.2.20)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
- C12Y402/02021—Chondroitin-sulfate-ABC exolyase (4.2.2.21)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Definitions
- TITLE COMPOSITIONS AND METHODS OF USING CHONDROITINASE ABCI MUTANTS
- the spinal cord is made up of nerve fibers. Damage to the central nervous system, including the spinal cord, results in a loss of function.
- the most common types of spinal cord injuries (SCI) include contusions (bruising of the spinal cord) and compression injuries (caused by prolonged pressure on the spinal cord).
- SCI spinal cord injuries
- the inability of axons to regenerate may lead to loss of sensation, loss of motor function and/or loss of autonomic function, as well as permanent paralysis.
- One reason that neurons fail to regenerate is their inability to traverse the glial scar that develops following a spinal cord injury.
- CSPGs chondroitin sulfate proteoglycans
- One embodiment of the present invention provides mutants of a chondroitinase ABCI enzyme.
- such chondroi ⁇ nase ABCl mutant enzymes exhibit enhanced activity.
- such chondroilinase ABCl mutant enzymes exhibit enhanced resistance to inaclivation, including inaclivation from UV or heat exposure.
- a chondroitinase ABCI mutant enzyme of the invention is selected from 055D2-3 (SEQ ID NO:1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057G1-1 (SKQ ID NO:4), 023G6-4 (SEQ ID NO:5) OO5B12-3 (SEQ ID NO: 6), and 021 B8-3 (SEQ ID NO:_).
- the nucleotide sequence of wild type chondroitinase ABCl of Proteus vulgaris is set forth as SEQ ID NO:7 and the amino acid sequence of chondroitinase ABCI is set forth as SEQ ID NO:8.
- the invention includes nucleic acids encoding the chondroitinase ABCI mutant enzymes of the invention and methods of their use.
- the invention includes a nucleic acid sequence that encodes a chondroitinase ABCI mutant enzyme selected from 055D2-3 (SEQ ID NO: 1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057Gl -1 (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005B12-3 (SEQ ID NO: 6), and 021 B8-3 (SEQ ID NO:_).
- a nucleic acid sequence of the invention is selected from 055D2-3 nucleic acid (SEQ ID NO:9), 079B6-2 nucleic acid (SEQ ID NO: 10), 079D2-2 nucleic acid (SKQ ID NO: l l), 057Gl -1 nucleic acid (SEQ ID NO: 12), 023G6-4 nucleic acid (SEQ ID NO: 13) 005Bl 2-3 nucleic acid (SEQ ID NO: 15), and 021B8-3 (SEQ ID NO:_J.
- an embodiment of the present invention relate to methods of treating a patient in need of neurological functional recovery, including sensory, motor and autonomic function, after, for example, central nervous system ("CNS") injury or disease.
- the ABCl mutant enzymes of the invention can also be used to degrade CSPGs.
- an embodiment of the invention includes a method of degrading one or more CSPGs using a composition comprising an ABCI mutant enzyme of the invention.
- composition of the invention effective for promoting neurological functional recovery comprises a chondroitinase ABCl mutant enzyme selected from 055D2-3 (SEQ ID NO: I), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3) : 057G1 -I (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005Bl 2-3 (SEQ ID NO: 6), and 021B8-3 (SEQ ID NO:_J.
- chondroitinase ABCl mutant enzyme selected from 055D2-3 (SEQ ID NO: I), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3) : 057G1 -I (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005Bl 2-3 (SEQ ID NO: 6), and 021B8-3 (SEQ ID NO:_J.
- One embodiment of the present invention is a method for modifying access of cells to extravascular spaces and regions, comprising administering to a patient a composition comprising an enzyme of the invention.
- Another embodiment of the present invention is a method of reducing penetration of cells associated with inflammation into tissue of a patient.
- the enzyme is selected from 055D2-3 (SEQ ID NO: 1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057Gl -1 (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005B 12-3 (SEQ ID NO: 6), and 021 B8-3 (SEQ ID NO:_J.
- Another embodiment of the present invention is a method for inhibiting extravasation of cells associated with inflammation from blood vessels, comprising administering to a patient a composition comprising an enzyme that cleaves chondroitin sulfate proteoglycans.
- an enzyme of the invention prevents cells selected from the group consisting of white blood cells, leukocytes, neutrophils, eosinophils, basophils, lymphocytes, B-cells, T-cells, monocytes, and macrophages from leaving the blood stream.
- the enzyme is selected from 055D2-3 (SKQ ID NO:1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057G1-1 (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005Bl 2-3 (SEQ ID NO: 6), and 021 B8-3 (SEQ ID NO:_).
- Another embodiment of the invention is a method of treating inflammation in a patient comprising administering to the patient an enzyme that cleaves chondroitin sulfate proteoglycans.
- the enzyme is selected from 055D2-3 (SEQ ID NO:1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057G1-1 (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005B12-3 (SKQ ID NO: 6), and 021B8-3 (SEQ ID NO:_).
- inflammation is associated with disease or injury, such as chronic inflammatory disease and central nervous system disease.
- Another embodiment of the invention is a method of preventing inflammation in a patient, comprising administering to the patient a composition comprising an enzyme that cleaves chondroitin sulfate proteoglycans.
- the enzyme is selected from 055D2-3 (SEQ ID NO'. l), 079B6-2 (SKQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057G1-1 (SEQ ID NO:4), 023G6-4 (SEQ ID N0:5) 005Bl 2-3 (SEQ ID NO: 6), and 021 B8-3 (SEQ ID NO:_J.
- Another embodiment of the present invention is a method of treating inflammation in a patient, comprising extracting cells associated with inflammation from a patient, subjecting the cells to an enzyme that cleaves chondroitin sulfate proteoglycans ex vivo to modify the cells, and administering the modified blood cells into the patient.
- the enzyme is selected from 055D2-3 (SEQ ID NO: 1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057Gl -1 (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005BI2-3 (SEQ ID NO: 6), and 021B8-3 (SEQ ID NO: ⁇ cauliflower
- an enzymes of the present invention is used to treat a patient in need of regeneration of damaged neurological tissue.
- an enzyme of the invention is used to facilitate diffusion and transport of therapeutic molecules capable of blocking and/or overcoming the activity of neuronal growth inhibitor)' molecules into damaged or diseased tissue.
- Embodiments of the present invention include compositions comprising chondroitinase ABCI mulant enzymes of the invention and methods for their use Io facilitate deliver)' and diffusion of therapeutics or diagnostic agents, and agents that promote regeneration of nerves and axons, into cells or tissues.
- a composition of the invention is effective in the regeneration of damaged neurological tissue or to facilitate diffusion or transport.
- a composition of the invention comprises a chondroitinase ⁇ BC1 mutant enzyme selected from 055D2-3 (SEQ ID NO. l), 079B6-2 (SEQ l ⁇ N0:2), 079D2-2 (SEQ ID N0:3), 057Gl -1 (SEQ ID NO:4). 023G6-4 (SEQ ID NO:5) 005B12-3 (SEQ ID NO: 6), and 021 B8-3 (SEQ ID NO:_).
- a composition of the invention effective for promoting neuronal outgrowth comprises a chondroitinase ABCI mutant enzyme selected from 055D2-3 (SEQ ID NO: I), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057G 1-1 (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005Bl 2-3 (SEQ ID NO: 6), and 021 B8-3 (SEQ ID NO:_J.
- FIG. 2 shows the results of a stability assay of mutant chondroitinase ABCI whole cell lysates at 37 0 C, as more fully described in Example 3.
- Figure 3 shows the results of a stability assay of semi-purified mutant chondroitinase ABCI enzymes, as more fully described in Example 4.
- the term "about” means plus or minus 10% of the numerical value of the number with which it is being used. Therefore, about 50% means in the range of 45%-55%.
- administering when used in conjunction with a therapeutic means to administer a therapeutic directly into or onto a target tissue or to administer a therapeutic to a patient whereby the therapeutic positively impacts the tissue to which it is targeted.
- the term '"administering can include, but is not limited to, providing an enzyme into or onto a target tissue; providing an enzyme systemically to a patient by, e.g., intravenous injection whereby the therapeutic reaches the target tissue; providing an enzyme in the form of the encoding sequence thereof to the target tissue (e.g., by so-called gene-therapy techniques).
- animal as used herein includes, but is not limited to, humans and non-human vertebrates such as wild, domestic and farm animals.
- the term “improves” is used to convey that the present invention changes either the appearance, form, characteristics and/or the physical attributes of the target to which it is being provided, applied or administered. The change may be demonstrated by any of the following alone or in combination, including degradation of the CSPGs of the lesi ⁇ ned area of the spinal cord or within the CNS or restoring, in whole or in part, motor, sensory or autonomic function of the mammal.
- the term “inhibiting” includes administering a compound of the present invention to prevent the onset of the symptoms, alleviating the symptoms, or eliminating the disease, condition or disorder.
- pharmaceutically acceptable it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
- recombinant protein refers to a polypeptide of the present invention which is produced by recombinant DNA techniques, wherein generally. DNA encoding a polypeptide is inserted into a suitable expression vector which is in turn used to transform a host cell to produce the protein. Moreover, the phrase "derived from.” with respect to a recombinant gene, is meant to include within the meaning of ''recombinant protein” those proteins having an amino acid sequence of a native protein, or an amino acid sequence similar thereto which is generated by mutations including substitutions and deletions (including truncation) of a naturally occurring form of the protein.
- the term "therapeutic" means an agent utilized to treat, combat, ameliorate, prevent or improve an unwanted condition or disease of a patient.
- embodiments of the present invention arc directed to the treatment of the central nervous system, such as degradation of the CSPGs of a lesioned area of spinal cord or within the CNS, or restoration, in whole or in part, of a motor, sensory or autonomic function of the mammal.
- Other embodiments of the invention are directed to inhibiting extravasation of cells.
- Yet other embodiments of the invention are directed to enhancing or facilitating diffusion, as discussed herein.
- Other embodiments of the invention are directed to treating or preventing inflammation.
- a therapeutically effective amount or “effective amount”, as used herein, may be used interchangeably and refer to an amount of a therapeutic compound component of the present invention.
- a therapeutically effective amount of a therapeutic compound is a predetermined amount calculated to achieve the desired effect, i.e., to effectively treat an injury to the central nervous system.
- a therapeutic compound comprising a therapeutically effective amount of a chondroitinase formulated to provide a stable, active enzyme, is sufficient to degrade the CSPOs of a lesioned area of the spinal cord or an amount sufficient to restore, in whole or in part, a motor, sensory or autonomic function of the mammal and may result in a regeneration of neurons in a central nervous system, such as by promoting axonal growth into an injured area.
- a therapeutically effective amount also includes an amount effective to degrade CSPGs and thereby promote recovery of neurological function.
- ⁇ therapeutically effective amount also includes an amount sufficient to modify extravasation of cells or to reduce or prevent inflammation.
- treat refers to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder or disease, or to obtain beneficial or desired clinical results.
- beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishmcnt of the extent of the condition, disorder or disease; stabilization (i.e., not worsening) of the state of the condition, disorder or disease; delay in onset or slowing of the progression of the condition, disorder or disease; amelioration of the condition, disorder or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder or disease.
- Treatment includes eliciting a clinically significant response without excessive levels of side effects. Treatment also includes prolonging survival as compared to expected survival if not receiving treatment.
- leukocyte is used to refer to the class of cells associated with intlammation, which may also be defined as any of the various blood cells that have a nucleus and cytoplasm. Also known as white blood cells, leukocytes include neutrophils, eosinophils, basophils, lymphocytes, such as B-cclls, T-cells, monocytes and macrophages.
- leukocytes arc particularly important in immune defense, including neutrophils, which release several antibacterial proteins; monocytes, which arc the precursors of macrophages that engulf and destroy foreign particles, and T and B lymphocytes, which are the antigen-recognizing cells of the immune cells.
- the term "vector” refers to a vehicle which can transport the nucleic acid molecules.
- the nucleic acid molecules encoding the chondroitinase polypeptide are covalently linked to the vector nucleic acid.
- the vector can be, for example, a plasmid, single or double stranded phage, a single or double stranded RNA or DNA viral vector, or artificial chromosome, such as a BAC, PAC, Y ⁇ C, OR MAC.
- One embodiment of the present invention provides mutants of chondroitinase ⁇ BCI.
- the chondroitinase ABCI mutant enzymes and nucleic acids encoding them are those of the isolated clones selected from 055D2-3 (deposited with American Type Culture Collection (ATCC), 10801 University Boulevard., Manassas, VA 201 10-2209 on
- ATCC deposits referred to herein will be maintained under the terms of the Budapest Treaty on the International Recognition of the Deposit of Micro-Organisms for purposes of Patent Procedure. These deposits are provided merely as convenience to those of skill in the art and are not an admission that a deposit is required under 35 U. S. C. ⁇ 1 12.
- sequence(s) of the polynucleotides contained in the deposited materials, as well as the amino acid sequence of the polypeptides encoded thereby, are incorporated herein by reference and are controlling in the event of any conflict with any description of sequences herein.
- a license may be required to make, use or sell die deposited materials, and no such license is hereby granted.
- One embodiment of the present invention provides mutants of chondroitinase ABCI.
- such chondroitinase ABCI mutant enzymes exhibit enhanced activity.
- an enzyme of the invention has an enzyme activity level (as measured by its ability to degrade a CSPG substrate) that is up to about two times greater than the activity level of the corresponding wild type enzyme.
- an enzyme of the invention has an enzyme activity level that is up to about three times greater than the activity of the corresponding wild type chondroitinase,
- the chondroitinase ABCI mutant enzymes are selected from 055D2-3 (SEQ ID NO.
- the enzyme is selected from the group consisting of 055D2-3 (SEQ ID NO: 1), 079B6-2 (SEQ ID NO:2), and 023G6-4 (SKQ ID NO:5).
- the invention includes nucleic acids encoding the chondroitinase ABCI mutant enzymes of the invention having enhanced activity, and methods of their use.
- the invention includes nucleic acid sequences that encode the chondroitinase ABCi mutant enzymes selected from 055D2-3 (SEQ ID NO: 1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SKQ ID NO:3), 057G1-1 (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005Bl 2-3 (SEQ ID NO: 6), and 021B8-3 (SKQ ID NO:_).
- a nucleic acid sequence of the invention is selected from 055D2-3 nucleic acid (SEQ ID NO:9), 079B6-2 nucleic acid (SEQ ID NO:10), 079D2-2 nucleic acid (SEQ ID NO: 1 1), 057G1 -1 nucleic acid (SEQ ID NO: 12), 023G6-4 nucleic acid (SEQ ID NO: 13) 005B12-3 nucleic acid (SEQ ID NO: 15), and 021 B8-3 (SKQ ID NO:_).
- such chondroilinasc ABCI mutant enzymes exhibit enhanced resistance to inactivation.
- enhanced resistance to inactivation permits an enzyme of the invention to remain active following a stress (such as heat or UV) for a time that is up to about ten-fold longer than for the corresponding wild type chondroitinase. For example, if a wild type chondroitinase maintains measureablc activity for up to about 3 days, a chondroilinasc enzyme of the invention maintains measurable activity for up to about 30 days under the same conditions.
- the chondroitinase ABCI mutant enzymes having increased resistance to inactivation are selected from 055D2-3 (SEQ ID NO:1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SKQ ID NO:3), 057G1-1 (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005Bl 2-3 (SEQ ID NO: 6), and 021B8-3 (SEQ ID NO:_J. More preferably, the enzyme is selected from the group consisting of 055D2-3 (SKQ ID NO: 1), 079B6-2 (SEQ ID NO:2), and 023G6-4 (SEQ ID NO:5).
- the invention includes nucleic acids encoding the chondroitinase ABCI mutant enzymes of the invention having enhanced resistance to inaclivation, and methods of their use.
- the invention includes nucleic acid sequences that encode the chondroitinase ABCl mutant enzymes selected from 055D2-3 (SEQ ID NO: 1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3) 5 057G1-1 (SKQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005Bl 2-3 (SKQ
- a nucleic acid sequence of the invention is selected from 055D2-3 nucleic acid (SEQ ID NO:9), 079B6-2 nucleic acid (SEQ ID NO: 10), 079D2-2 nucleic acid (SEQ ID NO:1 1), 057G1-1 nucleic acid (SEQ ID NO: 12), 023G6-4 nucleic acid (SEQ ID NO: 13) 005Bl 2-3 nucleic acid (SEQ ID NO: 15), and 021 B8-3 (SKQ ID NO:_J.
- a mutant chondroitinase ABCI enzyme having increased stability.
- the enzyme exhibits increased resistance to inactivation under stressed conditions, including exposure to UV light or heat, as compared to that of wild-type ABCI enzyme.
- the enzyme exhibits increased stability compared to wild-type chondroitinase ABCI enzyme following a challenge by a stress.
- the chondroitinase ABCI mutant enzymes having increased stability are selected from 055D2-3 (SEQ ID NO:1 ), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057GM (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005Bl 2-3 (SEQ ID NO: 6), and 02 I B8-3 (SKQ ID NO:_J. More preferably, the enzyme is selected from the group consisting of 055D2-3 (SEQ ID NO: 1). 079B6-2 (SEQ ID NO:2), and 023G6-4 (SEQ ID NO:5).
- the enzymes of the invention may be used to prevent, treat and alleviate symptoms of inflammation and inflammatory states.
- a chondroitinase ABCl mutant enzyme of the invention is used to prevent, treat or alleviate symptoms of chronic inflammatory diseases.
- a chondroitinase ABCI mutant enzyme of the invention may be used to treat inflammation associated with pain, injection and diseased stales.
- An enzyme of the invention may be used to prevent tissue damage that is associated with inflammatory processes. Several conditions, including chronic inflammatory diseases, may benefit from controlled immune response.
- Chronic inflammatory diseases include Asthma, Rheumatoid Arthritis (RA), Multiple Sclerosis (MS), Systemic Lupus Erythematosus (SLE), and Chronic Obstructive Pulmonary Disease (COPD).
- An enzyme of the invention may also be used to regulate the inflammatory state associated with one or more disease selected from the group consisting of central nervous system disorders, central nervous system diseases, spinal cord injury, and cardiovascular diseases.
- Inflammatory diseases, autoimmune diseases, and diseases with an inflammatory component that may be treated with a composition comprising an enzyme of the invention also include Multiple Sclerosis, Meningitis, Encephalitis, Rheumatoid arthritis, Osteo arthritis, Lupus, Wegener's granulomatosis, Inflammatory bowel disease: Crohn's colitis, ulcerative colitis, Asthma, Chlamydia infections, Syphilis, Thyroiditis, Temporal arteritis, Polymyalgia rhcumatica, Ankylosing spondylitis, Psoriasis, Vasculitiditis such as: temporal arteritis, Takayasu arteritis, syphilitic aortitis, infectious aneurisms, atherosclerotic aneurisms, inflammatory abdominal aortic aneurysms, polyarteritis nodosa, Kawasaki disease, Churg- Stra ⁇ ss, hyper
- One embodiment of the present invention is a method for modifying access of cells to cxtravascular spaces and regions comprising administering to a patient a composition comprising a chondroitinase ABCI mutant enzyme of the invention.
- Another embodiment of the present invention is a method of reducing penetration of cells associated with inflammation into tissue of a patient comprising administering to a patient a composition comprising an enzyme of the invention.
- Another embodiment of the invention is a method for inhibiting extravasation of cells associated with inflammation from blood vessels comprising administering to a patient a composition comprising a chondroitinase ABCI mutant enzyme of the invention.
- the enzyme of the invention may prevent extravasation of cells selected from the group selected from the group consisting of white blood cells, leukocytes, neutrophils, eosinophils, basophils, lymphocytes, B-cells, T-cclls, monocytes, and macrophages cells from leaving the blood stream.
- Another embodiment of the present invention is a method of treating inflammation in a patient, the method comprising extracting circulating cells from a patient, subjecting the cells to a chondroitinase ABCI mutant enzyme of the invention ex vivo to modify the cells, and administering the modified blood cells into the patient. Therefore, the use of the enzymes described herein may also be directed to ex vivo treatments.
- Extraction of cells may be accomplished by a variety of methods including, but not limited to, intravenous blood withdrawal, transfusion, dialysis, bypass, organ transplant and other similar methods that result in removal of cells from the body.
- Administration of the cells may be accomplished by the same methods used to extract the cells, including, but not limited to, intravenous administration, transfusion, dialysis, bypass, organ transplant and the like.
- ⁇ circulating leukocyte with ligands expressed on its surface containing carbohydrate chains may be extracted from a patient and modified ex vivo by one or more of the ABCI mutant enzymes of the invention. Extraction may be accomplished by blood draw, transfusion, dialysis, bypass, or organ transplant. As described, a chondroitinase ABCI mutant enzyme of the invention modifies the carbohydrate chains. Once modified, the leukocytes may be reintroduced into a patient's blood stream. Modified leukocytes will be incapable of adhering to endothelial expressed selcctins, mucins, and integrins.
- Timing of an extraction and reintroduction into the bloodstream may be optimized by observing the inflammatory response and the appearance of leukocytes in the blood stream, once said cells are signaled to specific sites of injury or infection.
- extravasation of leukocytes into tissue may be regulated, prevented, reduced, or controlled.
- Such regulation may be used in methods and treatments as directed to control and treat inflammatory response and diseases with an inflammatory component.
- compositions of the present invention can be used for the treatment of spinal cord injuries and in the promotion of regeneration of axons.
- the compositions of the present invention can also be used to promote plasticity, regrowth, repair, and/or regeneration of dysfunctional neurons in the CNS that have been damaged as a result of disease, such as degenerative diseases including Alzheimer's and Parkinson's disease.
- the use of proteoglycan degrading polypeptides or membrane transducing polypeptides in the compositions of the present invention also promote diffusion and access of damage or diseased tissue to other therapeutic agents promoting the regeneration of neurons.
- a further embodiment of the present invention is a method of treating central nervous system injuries comprising administering a composition comprising a chondroitinase ABCI mutant enzyme.
- the chondroitinase ABCI mutant enzyme is administered in a therapeutically effective amount.
- the chondroitinase ABCI mutant enzyme used for treating central nervous system injuries is selected from the group consisting of 055D2-3 (SEQ ID NO:1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SKQ ID NO:3), 057G1-1 (SHQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005B12-3 (SEQ ID NO: 6), and 021B8-3 (SEQ ID NO:__). More preferably, the enzyme is selected from the group consisting of 055D2-3 (SEQ ID NO:1 ), 079B6-2 (SEQ ID NO:2), and 023G6-4 (SEQ ID NO:5).
- Such central nervous system injuries may include, but arc not limited to, spinal cord injuries, including trauma induced injuries, contusions, or compress injuries.
- Another embodiment of the present invention is a method promoting neuronal outgrowth comprising administering a composition comprising a chondroitinase ABCI mutant enzyme.
- the chondroitinase ABCI mutant enzyme is administered in a therapeutically effective amount.
- the chondroitinase ABCI mutant enzyme that promotes neuronal outgrowth is selected from the group consisting of 055D2-3 (SEQ ID NO:1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057G1-1 (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005Bl 2-3 (SEQ ID NO: 6), and 021B8-3 (SEQ ID NO:_J. More preferably, the enzyme is selected from the group consisting of 055D2-3 (SEQ ID NO: 1). 079B6-2 (SEQ ID NO:2), and 023G6-4 (SEQ ID NO:5).
- chondroitinase ABCI mutant enzyme is administered in a therapeutically effective amount.
- the present invention is directed to a method of utilizing chondroitinase to promote sensory, motor or autonomic neurological functional recovery following injury in or to the spinal cord.
- Compositions useful in this method include acceptable formulations of a chondroitinase ABCI mutant enzyme of the invention, including, for example, immediate release and sustained release formulations of enzyme.
- the present invention is also directed to a method of promoting neurological functional recovery after a contusion injury to the spinal cord.
- an embodiment of the invention includes a method of degrading one or more CSPGs using a composition comprising an ABCI mutant enzyme of the invention.
- a composition of the invention effective for promoting neurological functional recover ⁇ ' comprises a chondroitinase ⁇ BCI mutant enzyme selected from 055D2-3 (SEQ ID NO: 1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057Gl -I (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005B12-3 (SEQ ID NO: 6), and O21B8-3 (SEQ ID NO:_J.
- a chondroitinase ⁇ BCI mutant enzyme selected from 055D2-3 (SEQ ID NO: 1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057Gl -I (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005B12-3 (SEQ ID NO: 6), and O21B8-3 (SEQ ID NO:_J.
- compositions and a method for its use that facilitates the access and distribution of a therapeutic and diagnostic agent in the composition into cells, through membranes or into tissues by the use of composition that includes at least one enzyme capable of cleaving proteoglycans.
- the composition comprises a chondroitinase ⁇ BCI mutant enzyme selected from 055D2-3 (SEQ ID NO:1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057G1-1 (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005Bl 2-3 (SEQ ID NO: 6), and 021 B8-3 (SEQ ID NO:_J.
- the molecules or agents in the composition may include one or more of growth factors including, for example, Brain Derived Neurotrophic Factor, Insulin-like Growth Factor, Fibroblast Growth Factor. Ciliary Neurotrophic Factor, Glial Derived Neurotrophic Factor, Transforming Growth Factor, Glial Growth Factor 2, Ll , GMl , Vascular Endothelial Growth Factor, Nerve Growth Factor, and Immunophilins.
- the composition in some embodiments comprises a fluorescent or contrast agent for imaging.
- the agent includes a cell for transplant, for example a stem cell or neuron, a cell as a deliver ⁇ ' agent, a chemotherapeutic agent, an antibiotic, an antibody, or a Nogo receptor antagonist.
- the compositions can be used for treating a CNS injury. Preferably the composition is used in the treatment of neuronal damage from a contusion injury.
- the treatments described herein deliver an amount of a chondroitinase ABCI mutant enzyme effective to degrade CSPGs and thereby promote, for example, the recovery of neurological function, optionally including a therapeutic agent, to the CNS.
- Such methods may include optionally administering, in combination with a chondroitinase ABCI mutant enzyme of the invention, another chondroitinase, including, but not limited to chondroitinase ABCI, chondroitinase ABCII, chondroitinase AC and chondroitinase B or co-administering a mammalian enzyme with chondroitinase-like activity, such as hyaluronidases Hyall, Hyal2, Hyal3, IIyal4, and PH20 preferably to the CNS, and more preferably to the lesions of the injured area of the CNS.
- Chondroitinase may be obtained from various sources, including a microorganism that naturally expresses a chondroitinase; for example, but not limited to, E. coli, Proteus vulgaris, or from the expression of a recombinant protein in a host cell.
- the host cell can be a prokaryotic cell (such as E. coli) or a eukaryolic cell (such as yeast, a mammalian cell or an insect cell).
- the chondroitinase ⁇ BC1 mutant nucleic acids of the present invention may be obtained by a number of methods known in the art. For example, one may use the polymerase chain reaction and/or other techniques to generate mutations in the wild type P. vulgaris or other chondroitinase encoding sequence.
- the invention includes a method of making a nucleic acid sequence that encodes a chondroitinase ⁇ BC1 mutant enzyme selected from 055D2-3 (SEQ ID NO: 1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID N ⁇ :3), 057G1 -1 (SEQ ID NO:4), 023G6-4 (SEQ ID NO:5) 005Bl 2-3 (SEQ ID NO: 6), and 021B8-3 (SEQ ID NO:
- the invention includes a method of making a nucleic acid sequence of the invention, wherein the nucleic acid is selected from 055D2-3 nucleic acid (SEQ ID NO:9), 079B6-2 nucleic acid (SEQ ID NO:10), 079D2-2 nucleic acid (SEQ ID NO: 1 1), 057G1-1 nucleic acid (SEQ ID NO:12), 023G6-4 nucleic acid (SEQ ID NO:13) 005B12-3 nucleic acid (SEQ ID NO: 15), and 021 B8-3 (SEQ ID NO:. J.
- Expression of a recombinant ABCl mutant nucleic acid sequence of the invention can be performed by ligating a nucleic acid encoding the ABCI mutant protein, or a portion thereof, into a vector suitable for expression in either prokaryotic cells, eukaryotic cells, or both. Procedures for ligation are well known to those of ordinary skill in the art. Expression vectors for production of recombinant forms of the subject chondroitinase polypeptides include plasmids and other vectors.
- suitable vectors for the expression of a chondroitinase ABCl mutant polypeptide include plasmids of the types: pBR322-derived plasmids, pEMBL- derivcd plasmids, pEX-dcrived plasmids, pBTac-derived plasmids and pUC-derived plasmids for expression in prokaryotic cells, such as E. coli.
- YEP24, YIP5, YEP51, YEP52, pYES2, and YRP 17 are cloning and expression vehicles useful in the introduction of genetic constructs into S. cerevisiae (sec, for example, Broach ct al. (1983) in Experimental Manipulation of Gene Expression, ed. M. lnouyc Academic Press, p. 83, incorporated by reference herein).
- a chondroitinase ABCI mutant polypeptide of the invention is produced recombinantly utilizing an expression vector generated by subcloning the coding sequence of one of the chondroitinase proteins represented in 055U2-3 (SHQ ID NO: 1), 079B6-2 (SEQ ID NO:2), 079D2-2 (SEQ ID NO:3), 057G1-1 (SEQ ID NO:4), 023G6-4 (SEQ ID N0:5) 005 B 12-3 (SEQ ID NO: 6), and 021 B8-3 (SEQ ⁇ D N0:_).
- a recombinant chondroitinase ABCI mutant polypeptide of the invention by the use of an insect expression system such as the baculovirus expression system.
- insect expression system such as the baculovirus expression system.
- bac ⁇ lovirus expression systems include pVL- derived vectors (such as pVL1392, pVL1393 and pVL941), pAcUW-derived vectors (such as p ⁇ cUWl), and pBlueBac-derivcd vectors (such as the ⁇ -gal containing pBlueBac III).
- the enzymes of the invention may be formulated into pharmaceutical compositions and formulations. Suitable stable formulations and methods of purification are set forth in co-pending FCT Application No. US2005/017464 filed May 18, 2005 entitled “Methods of Purifying Chondroitinase and Stable Formulations Thereof herein incorporated by reference in its entirety.
- chondroitinase ABCl mutant enzyme of the invention for both storage and administration.
- the enzyme of such stable formulations exhibit at least about 50% of activity at about 24 hours, preferably at least about 75% of activity, more preferably at least about 85% of activity.
- the formulations consistently provide stable chondroitinase activity.
- the chondroitinase is formulated in a phosphate buffer, preferably a sodium phosphate buffer with a concentration in the range of about 50 mM to about 1 M.
- a preferred embodiment is about 750 mM sodium phosphate.
- Another preferred embodiment is about 100 mM sodium phosphate.
- the chondroitinase may be formulated in a sodium phosphate buffer that further comprises sodium acetate.
- Sodium acetate may be present in the range of 25 mM to about 75 mM.
- the sodium acetate concentration is about 50 mM.
- a preferred formulation for administration is a chondroitinase in a buffer with a pi 1 of about 7.4. Further embodiments of formulations for storage and administration arc provided in the Examples described.
- a formulation comprising a purified chondroitinase ⁇ BCI mutant enzyme of the invention and a buffer comprising an increased ionic strength.
- a formulation comprises an increased ionic concentration may increase stability of an enzyme formulation.
- a preferred embodiment provides a formulation with about 1 M NaCl in sodium phosphate.
- the concentration of sodium phosphate may be about 50 mM.
- the enzyme storage concentration is below about 0.4 mg/ml.
- a chondroitinase ABCl mutant enzyme formulation comprises about 0.4 mg/ml of a chondroitinase ⁇ BCI mutant enzyme of the invention in about 100 mM Na phosphate, at a pH of about 7.4 with a preferred substrate specificity for chondroitin ⁇ , B, and C about the same.
- chondroitinase ⁇ BCI mutant enzyme of the invention for both storage and administration.
- the enzyme of such stable formulations exhibit at least about 50% of activity at about 24 hours, preferably at least about 75% of activity, more preferably at least about 85% of activity.
- the formulations consistently provide stable chondroitinase activity.
- a chondroitinase ABCI mutant enzyme purification comprising the following steps: 1 ) extracting the enzyme from a cell, 2) separating the crude cell extract using cation-exchange chromatography, 3) further separating Uie extract by a gel filtration chromatography, and 4) removing endotoxin through an anion-exchange membrane to produce a purified chondroitinase ABCl mutant enzyme of the invention.
- a purified chondroitinase ABCI of the invention is dialyzed into a volatile buffer, lyophilized and stored at " 80 0 C.
- Stabilizers include carbohydrates, amino acids, fatty acids, and surfactants and are known to those skilled in the art. Examples include carbohydrates such as sucrose, lactose, mannitol, and dextran, proteins such as albumin and protamine, amino acids such as arginine, glycine, and threonine, surfactants such as ⁇ WEEN® and PLURONIC®, salts such as calcium chloride and sodium phosphate, and lipids such as fatty acids, phospholipids, and bile salts.
- Chondroitinase ⁇ BCf mutant enzymes of the invention may be administered topically, locally or systemically. Topical or local administration is preferable for greater control of application.
- ⁇ n enzyme of the invention singularly or in combination with other enzymes of the invention or with other CSPG-dcgrading enzymes, can be mixed with an appropriate pharmaceutical carrier prior to administration. Administration includes delivery of the enzyme to the site of injury or site at which CSPGs to be degraded are found.
- Examples of generally used pharmaceutical carriers and additives are conventional diluents, binders, lubricants, coloring agents, disintegrating agents, buffer agents, isotonizing fatty acids, isotonizing agents, preservanls, anesthetics, surfactants and the like, and are known to those skilled in the art.
- Pharmaceutical carriers that may be used include dextran, sucrose, lactose, maltose, xylose, trehalose, mannitol. xylitol, sorbitol, inositol, serum albumin, gelatin, creatinine, polyethlene glycol, non-ionic surfactants (e.g. polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hardened castor oil, sucrose fatty acid esters, polyoxyethylene polyoxypropylcnc glycol) and similar compounds.
- non-ionic surfactants e.g. polyoxyethylene sorbitan fatty acid esters, polyoxyethylene hardened
- a treatment regimen according to the invention may be carried out by a means of administering a composition comprising a chondroitinase ABCI mutant enzyme of the present invention.
- the treatment regimen may further comprise administering chondroitinase ABCI, chondroitinase ⁇ BCII, chondroitinase AC and chondroitinase B or mammalian enzymes with chondroitinase-like activity such as hyaluronidases Hyal l, Hyal2, Hyal3, I lyal4 and PI 120 to the lesions of the injured area of the CNS.
- the mode of administration, the timing of administration and the dosage arc carried out such that the functional recovery from impairment of the CNS is enhanced by the promotion of ncurite outgrowth.
- the effective amount of chondroitinase can be administered in a single dosage, two dosages or a plurality of dosages.
- the dosage may be administered at any time, in one embodiment, the dosage is administered within 12 hours after injury, or as soon as is feasible.
- the dosage is administered to an injured mammal in one, two or a plurality of dosages; such dosages would be dependant on the severity of the injury and the amount of CSPGs present in the glial scarring.
- a plurality of dosages may be delivered on a daily, weekly, or bi-weekly basis.
- the deliver)' of the dosages may be by means of catheter or syringe.
- the treatment can be administered during surgery to allow direct application to the glial scar.
- the invention is directed to a pharmaceutical composition comprising a compound, as defined above, and a pharmaceutically acceptable carrier or diluent, or an effective amount of a pharmaceutical composition comprising a compound as defined above.
- the compounds of the present invention can be administered in the conventional manner by any route where they are active. Administration can be systemic, topical, or oral. For example, administration can be, but is not limited to, parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, oral, buccal, or ocular routes, or intravaginally, by inhalation, by depot injections, or by implants.
- modes of administration for the compounds of the present invention can be, bul are not limited to, sublingual, injectable (including short-ac ⁇ ng, depot, implant and pellet forms injected subcutancously or intramuscularly), or by use of vaginal creams, suppositories, pessaries, vaginal rings, rectal suppositories, intrauterine devices, and transdermal forms such as patches and creams.
- Specific modes of administration will depend on the indication.
- the selection of the specific route of administration and the dose regimen is to be adjusted or titrated by the clinician according to methods known to the clinician in order to obtain the optimal clinical response.
- the amount of compound to be administered is that amount which is therapeutically effective.
- the dosage to be administered will depend on the characteristics of the subject being treated, e.g., the particular animal treated, age, weight, health, types of concurrent treatment, if any, and frequency of treatments, and can be easily determined by one of skill in the art (e.g., by the clinician).
- compositions containing the compounds of the present invention and a suitable carrier can be solid dosage forms which include, but are not limited to. tablets, capsules, cachets, pellets, pills, powders and granules; topical dosage forms which include, but arc not limited to, solutions, powders, fluid emulsions, fluid suspensions, semi-solids, ointments, pastes, creams, gels and jellies, and foams; and parenteral dosage forms which include, but are not limited to, solutions, suspensions, emulsions, and dry powder; comprising an effective amount of a polymer or copolymer of the present invention.
- the active ingredients can be contained in such formulations with pharmaceutically acceptable diluents, fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like.
- pharmaceutically acceptable diluents fillers, disintegrants, binders, lubricants, surfactants, hydrophobic vehicles, water soluble vehicles, emulsifiers, buffers, humectants, moisturizers, solubilizers, preservatives and the like.
- the means and methods for administration arc known in the art and an artisan can refer to various pharmacologic references for guidance. For example, Modern Pharmaceutics, Banker & Rhodes, 4 th Ed., Informa Healthcare (2002); and Goodman & Gilman's The Pharmaceutical Basis of Therapeutics, 10th Ed., McGraw-Hill (2001 ) can be consulted
- the compounds of the present invention can be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
- the compounds can be administered by continuous infusion subcutancously over a period of about 15 minutes to about 24 hours.
- Formulations for injection can be presented in unit dosage form, e.g., in ampoules or in multi-dose containers, with an added preservative.
- the compositions can take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and can contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
- the compounds can be formulated readily by combining these compounds with pharmaceutically acceptable carriers well known in the art.
- Such carriers enable the compounds of the invention to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
- Pharmaceutical preparations for oral use can be obtained by adding a solid excipient, optionally grinding the resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- Suitable excipients include, but are not limited to, fillers such as sugars, including, but not limited to, lactose, sucrose, mannitol, and sorbitol; cellulose preparations such as, but not limited to, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and polyvinylpyrrolidone (PVP).
- disintegrating agents can be added, such as, but not limited to, the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores can be provided with suitable coatings.
- suitable coatings for this purpose, concenirated sugar solutions can be used, which can optionally contain gum arabic, talc, polyvinyl pyrrolidone. carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dycstuf ⁇ s or pigments can be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
- compositions which can be used orally include, but are not limited to, push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as, e.g., lactose, binders such as, e.g., starches, and/or lubricants such as, e.g., talc or magnesium stearate and, optionally, stabilizers.
- the active compounds can be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers can be added. All formulations for oral administration should be in dosages suitable for such administration.
- compositions can take the form of, e.g., tablets or lozenges formulated in a conventional manner.
- the compounds for use according to the present invention are conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propcllant, e.g.. dichlorodifluoromcthanc, trichlorofiuoromcthanc, dichlorotcrrafluoroethane, carbon dioxide or other suitable gas.
- a suitable propcllant e.g.. dichlorodifluoromcthanc, trichlorofiuoromcthanc, dichlorotcrrafluoroethane, carbon dioxide or other suitable gas.
- the dosage unit can be determined by providing a valve to deliver a metcred amount.
- Capsules and cartridges of, e.g., gelatin for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
- the compounds of the present invention can also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
- the compounds of the present invention can also be formulated as a depot preparation.
- Such long acting formulations can be administered by implantation (for example subcutaneously or intramuscularly) or by intramuscular injection.
- the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
- the compounds of the present invention for example, can be applied to a plaster, or can be applied by transdermal, therapeutic systems that are consequently supplied to the organism.
- compositions of the compounds also can comprise suitable solid or gel phase carriers or cxcipients.
- suitable solid or gel phase carriers or cxcipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as, e.g., polyethylene glycols.
- the compounds of the present invention can also be administered in combination with other active ingredients, such as, for example, adjuvants, protease inhibitors, or other compatible drugs or compounds where such combination is seen to be desirable or advantageous in achieving the desired effects of the methods described herein.
- active ingredients such as, for example, adjuvants, protease inhibitors, or other compatible drugs or compounds where such combination is seen to be desirable or advantageous in achieving the desired effects of the methods described herein.
- the present example illustrates the generation of exemplary chondroitinase ABCI mutant enzymes and nucleic acids according to the present invention.
- Random mutagenesis of cABCl The chondroitinase ABCl gene was divided into four modules. Random mutagenesis was performed on each individual module, using the Genemorph II kit (Stratagene) to create a product containing 1 -2 amino acid changes per mutant. Products were cloned and transformed into E. coli DHlOB such that the number of colonies obtained containing the correct clone structure was at least 5-times the number of individual mutant genes predicted to exist in the DNA population. The colonies were pooled and plasmid DNA was purified and used to transform the expression strain, BL21.
- the total size of this library is 1089 variant cABCI sequences.
- the number of colonies obtained containing the correct clone structure was at least 5-timcs the number of individual mutant genes predicted.
- the ligation was weighted to mostly produce clones containing two or three mutant modules, thereby creating new combinations of the mutations identified in the initial screening "hits.”
- the present example illustrates exemplary chondroitinase mutant enzymes of the present invention.
- Table 1B Time (days) at 37 degrees C (continued)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES07853916.0T ES2473610T3 (en) | 2006-10-10 | 2007-10-10 | Compositions and methods of using ABCI chondroitinase mutants |
EP07853916.0A EP2079835B1 (en) | 2006-10-10 | 2007-10-10 | Compositions and methods of using chondroitinase abci mutants |
AU2007307736A AU2007307736C1 (en) | 2006-10-10 | 2007-10-10 | Compositions and methods of using chondroitinase ABCI mutants |
CA2666536A CA2666536C (en) | 2006-10-10 | 2007-10-10 | Compositions and methods of using chondroitinase abci mutants |
JP2009532566A JP5391069B2 (en) | 2006-10-10 | 2007-10-10 | Compositions and methods using chondroitinase ABCI variants |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82880006P | 2006-10-10 | 2006-10-10 | |
US60/828,800 | 2006-10-10 |
Publications (4)
Publication Number | Publication Date |
---|---|
WO2008045970A2 true WO2008045970A2 (en) | 2008-04-17 |
WO2008045970A3 WO2008045970A3 (en) | 2008-11-27 |
WO2008045970A8 WO2008045970A8 (en) | 2012-11-29 |
WO2008045970A9 WO2008045970A9 (en) | 2013-06-20 |
Family
ID=39283608
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/081001 WO2008045970A2 (en) | 2006-10-10 | 2007-10-10 | Compositions and methods of using chondroitinase abci mutants |
Country Status (7)
Country | Link |
---|---|
US (5) | US7722864B2 (en) |
EP (2) | EP2079835B1 (en) |
JP (1) | JP5391069B2 (en) |
AU (1) | AU2007307736C1 (en) |
CA (3) | CA3009034C (en) |
ES (2) | ES2642088T3 (en) |
WO (1) | WO2008045970A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010100247A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
US8679481B2 (en) | 2003-05-16 | 2014-03-25 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
US8785606B2 (en) | 2002-05-04 | 2014-07-22 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
US8906363B2 (en) | 2003-05-16 | 2014-12-09 | Acorda Therapeutics, Inc. | Fusion proteins for the treatment of CNS |
US9102930B2 (en) | 2006-10-10 | 2015-08-11 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US9402886B2 (en) | 2005-09-26 | 2016-08-02 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140212404A1 (en) * | 2012-11-14 | 2014-07-31 | Khizer Khaderi | Compositions and Methods for Treating Injuries to the Visual System of a Human |
CN111518822B (en) * | 2019-07-02 | 2022-08-09 | 江南大学 | Chondroitin sulfate ABC lyase mutant and secretory expression method thereof |
US20210362261A1 (en) * | 2020-05-20 | 2021-11-25 | Crc-Evans Pipeline International, Inc. | Pipeline handler with welder |
CN116790571B (en) * | 2023-05-17 | 2024-06-11 | 西南大学 | High-thermal-stability endo-alginic acid lyase mutant based on rational design modification and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004103299A2 (en) | 2003-05-16 | 2004-12-02 | Acorda Therapeutics, Inc. | Compositions and methods for the treatment of cns injuries |
WO2005087920A2 (en) | 2004-03-10 | 2005-09-22 | Massachusetts Institute Of Technology | Recombinant chondroitinase abc i and uses thereof |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270194A (en) * | 1989-08-31 | 1993-12-14 | Instrumentation Laboratory Spa | Stabilized glucose oxidase from Aspergillus Niger |
CA2071898A1 (en) | 1989-10-27 | 1991-04-28 | Diane M. Snow | Inhibition of cell growth by keratan sulfate, chondroitin sulfate, dermatan sulfate and other glycans |
US5804604A (en) * | 1989-12-21 | 1998-09-08 | Biogen, Inc. | Tat-derived transport polypeptides and fusion proteins |
US5747641A (en) * | 1989-12-21 | 1998-05-05 | Biogen Inc | Tat-derived transport polypeptide conjugates |
US5679650A (en) | 1993-11-24 | 1997-10-21 | Fukunaga; Atsuo F. | Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine |
US5262522A (en) * | 1991-11-22 | 1993-11-16 | Immunex Corporation | Receptor for oncostatin M and leukemia inhibitory factor |
US5496718A (en) * | 1992-06-26 | 1996-03-05 | Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) | Chondroitinase ABC isolated from proteus vulgaris ATCC 6896 |
JP3980657B2 (en) | 1992-06-26 | 2007-09-26 | 生化学工業株式会社 | Chondroitinase ABC, process for producing the same and pharmaceutical composition |
US7008783B1 (en) * | 1992-09-22 | 2006-03-07 | Maruha Corporation | Gene encoding chondroitinase ABC and uses therefor |
EP0702715A4 (en) | 1993-04-23 | 2000-01-19 | American Cyanamid Co | CLONING AND EXPRESSION OF THE CHONDROITINASE I AND II GENES FROM $i(P. VULGARIS) |
US5578480A (en) | 1993-04-23 | 1996-11-26 | American Cyanamid Company | Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris |
US6248562B1 (en) * | 1993-11-01 | 2001-06-19 | Research Foundation State University Of New York | Chimeric proteins comprising borrelia polypeptides and uses therefor |
AU1176595A (en) | 1993-11-12 | 1995-05-29 | International Technology Management Associates, Ltd. | Methods of repairing connective tissues |
US6570617B2 (en) * | 1994-01-28 | 2003-05-27 | California Institute Of Technology | CMOS active pixel sensor type imaging system on a chip |
US5498536A (en) * | 1994-04-22 | 1996-03-12 | American Cyanamid Company | Chondroitinase II from Proteus vulgaris |
CA2151547C (en) | 1994-06-10 | 2010-10-12 | Elliott A. Gruskin | Recombinant chimeric proteins and methods of use thereof |
US6093563A (en) | 1994-07-08 | 2000-07-25 | Ibex Technologies R And D, Inc. | Chondroitin lyase enzymes |
US5997863A (en) | 1994-07-08 | 1999-12-07 | Ibex Technologies R And D, Inc. | Attenuation of wound healing processes |
US6326166B1 (en) * | 1995-12-29 | 2001-12-04 | Massachusetts Institute Of Technology | Chimeric DNA-binding proteins |
EP0807181A1 (en) | 1995-02-03 | 1997-11-19 | G.D. Searle & Co. | NOVEL c-MPL LIGANDS |
US5792743A (en) | 1995-04-19 | 1998-08-11 | Acorda Therapeutics | Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule |
US6313265B1 (en) | 1995-07-24 | 2001-11-06 | The Scripps Research Institute | Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use |
US5869301A (en) * | 1995-11-02 | 1999-02-09 | Lockhead Martin Energy Research Corporation | Method for the production of dicarboxylic acids |
JP3702450B2 (en) | 1996-12-18 | 2005-10-05 | ニプロ株式会社 | Reagent for lactate dehydrogenase measurement |
US6200564B1 (en) * | 1997-04-11 | 2001-03-13 | J. Thomas Lamont | Pharmaceutical compositions containing chondroitinase and uses therefor |
JP4172842B2 (en) | 1997-05-02 | 2008-10-29 | 生化学工業株式会社 | Chondroitinase composition |
DE69829605T2 (en) | 1997-05-02 | 2006-02-09 | Seikagaku Corp. | Chondroitinase-containing compositions |
DK0900569T3 (en) * | 1997-08-22 | 2003-01-27 | Seikagaku Kogyo Co Ltd | Therapeutic agent for the treatment of herniaric intervertebral disc |
US6153187A (en) * | 1997-09-02 | 2000-11-28 | Insight Strategy & Marketing Ltd. | Use of glycosaminoglycans degrading enzymes for management of airway associated diseases |
US20010006630A1 (en) | 1997-09-02 | 2001-07-05 | Oron Yacoby-Zeevi | Introducing a biological material into a patient |
DK1887014T3 (en) | 1997-10-17 | 2010-08-02 | Genentech Inc | Human Toll Homologs |
WO1999040787A1 (en) | 1998-02-13 | 1999-08-19 | Medinox, Inc. | Modified pharmacologically active agents and improved therapeutic methods employing same |
JP2002505873A (en) | 1998-03-13 | 2002-02-26 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | Vascular endothelial growth factor 2 |
AU3006899A (en) | 1998-03-13 | 1999-09-27 | Biomarin Pharmaceutical Inc. | Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment |
US6171575B1 (en) * | 1998-04-06 | 2001-01-09 | Shinichi Okuyama | Method of radioisotopic assessment of the integrity and function of the nose-brain barrier |
JP2003527822A (en) * | 1998-08-27 | 2003-09-24 | マサチューセッツ インスティテュート オブ テクノロジー | Rationally designed heparinases from heparinases I and II |
MXPA01003538A (en) * | 1998-10-06 | 2005-09-08 | Rush Presbyterian St Luke | Method for the treatment of chemonucleolysis. |
JP2003514765A (en) | 1999-02-28 | 2003-04-22 | ワシントン ユニバーシティー | Novel transducing molecules and methods of use |
WO2000059942A2 (en) | 1999-04-02 | 2000-10-12 | Eli Lilly And Company | Human obesity protein binding protrein-2 homolog and uses thereof |
SE9901428D0 (en) | 1999-04-21 | 1999-04-21 | Karolinska Innovations Ab | Amphibodies |
BRPI0011407B8 (en) | 1999-06-08 | 2021-05-25 | Regeneron Pharma | chimeric nucleic acid molecule, fusion polypeptide, expression vector, host vector system, and methods of producing a fusion polypeptide |
WO2001039795A2 (en) | 1999-12-02 | 2001-06-07 | Ibex Technologies, Inc. | Attenuation of fibroblast proliferation |
AU2001272968C1 (en) | 2000-06-22 | 2008-06-05 | Amgen Inc. | Il-17 molecules and uses thereof |
US20020142299A1 (en) | 2001-01-09 | 2002-10-03 | Davidson Beverly L. | PTD-modified proteins |
ATE382704T1 (en) | 2001-02-15 | 2008-01-15 | Univ Chicago | METHOD FOR DETECTING IN YEAST FOR MEANS OF INFLUENCING PROTEIN FOLDING |
CA2367636C (en) | 2001-04-12 | 2010-05-04 | Lisa Mckerracher | Fusion proteins |
WO2003000901A2 (en) | 2001-06-26 | 2003-01-03 | Decode Genetics Ehf. | Nucleic acids encoding protein kinases |
CA2455827C (en) * | 2001-08-13 | 2015-06-09 | University Of Florida Research Foundation, Inc. | Materials and methods for nerve grafting comprising degrading chondroitin sulfate proteoglycan |
US20030049258A1 (en) | 2001-09-11 | 2003-03-13 | Martin Ungerer | Method of increasing the contractility of a heart, a heart muscle or cells of a heart muscle |
AU2002340119A1 (en) | 2001-10-09 | 2003-04-22 | Immunex Corporation | Mammalian c-type lectins |
US20030127812A1 (en) | 2002-01-04 | 2003-07-10 | Charles Mehrmann | Bi-directional sliding board |
GB0205022D0 (en) | 2002-03-04 | 2002-04-17 | Univ Cambridge Tech | Materials and methods for the treatment of cns damage |
WO2004108069A2 (en) * | 2002-05-04 | 2004-12-16 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
WO2003100031A2 (en) | 2002-05-20 | 2003-12-04 | Board Of Regents, The University Of Texas System | Methods and compositions for delivering enzymes and nucleic acid molecules to brain, bone, and other tissues |
ATE481478T1 (en) * | 2002-06-03 | 2010-10-15 | Massachusetts Inst Technology | RATIONALLY DESIGNED LYASES DERIVED FROM CHONDROITINASE B |
US7163545B2 (en) * | 2002-07-29 | 2007-01-16 | Mayo Foundation For Medical Education And Research | Spinal cord surgical implant |
JP4527950B2 (en) | 2002-08-09 | 2010-08-18 | シスメックス株式会社 | Lipid measuring reagent |
US7074581B2 (en) * | 2002-08-09 | 2006-07-11 | Sysmex Corporation | Reagent for assaying lipid |
PT1534736E (en) * | 2002-08-10 | 2010-09-07 | Univ Yale | Nogo receptor antagonists |
AU2003265561A1 (en) | 2002-08-15 | 2004-03-03 | Acorda Therapeutics, Inc. | Chimeric protein |
JP2004113166A (en) | 2002-09-27 | 2004-04-15 | Mitsui Chemicals Inc | Method for stabilizing haloperoxidase activity |
EP2354155B1 (en) * | 2003-05-16 | 2017-05-03 | Acorda Therapeutics, Inc. | Fusion Proteins for Treatment of CNS |
EP3211084B1 (en) * | 2003-05-16 | 2019-03-27 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of cns |
US7959914B2 (en) * | 2003-05-16 | 2011-06-14 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
CA2566731C (en) | 2004-05-18 | 2012-07-24 | Acorda Therapeutics, Inc. | Methods of purifying chondroitinase and stable formulations thereof |
CA2623635C (en) | 2005-09-26 | 2013-04-02 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase abci mutants |
US7722864B2 (en) | 2006-10-10 | 2010-05-25 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
-
2007
- 2007-10-10 US US11/870,350 patent/US7722864B2/en not_active Expired - Fee Related
- 2007-10-10 EP EP07853916.0A patent/EP2079835B1/en active Active
- 2007-10-10 AU AU2007307736A patent/AU2007307736C1/en not_active Ceased
- 2007-10-10 ES ES12153026.5T patent/ES2642088T3/en active Active
- 2007-10-10 EP EP12153026.5A patent/EP2450442B1/en active Active
- 2007-10-10 CA CA3009034A patent/CA3009034C/en not_active Expired - Fee Related
- 2007-10-10 CA CA3086902A patent/CA3086902C/en not_active Expired - Fee Related
- 2007-10-10 JP JP2009532566A patent/JP5391069B2/en not_active Expired - Fee Related
- 2007-10-10 CA CA2666536A patent/CA2666536C/en not_active Expired - Fee Related
- 2007-10-10 ES ES07853916.0T patent/ES2473610T3/en active Active
- 2007-10-10 WO PCT/US2007/081001 patent/WO2008045970A2/en active Application Filing
-
2010
- 2010-05-17 US US12/781,762 patent/US8404232B2/en active Active
-
2013
- 2013-03-22 US US13/849,420 patent/US9102930B2/en not_active Expired - Fee Related
-
2015
- 2015-07-02 US US14/790,075 patent/US9410141B2/en not_active Expired - Fee Related
-
2016
- 2016-08-05 US US15/230,040 patent/US9987340B2/en not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004103299A2 (en) | 2003-05-16 | 2004-12-02 | Acorda Therapeutics, Inc. | Compositions and methods for the treatment of cns injuries |
WO2005087920A2 (en) | 2004-03-10 | 2005-09-22 | Massachusetts Institute Of Technology | Recombinant chondroitinase abc i and uses thereof |
Non-Patent Citations (1)
Title |
---|
See also references of EP2079835A4 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8785606B2 (en) | 2002-05-04 | 2014-07-22 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
US9956273B2 (en) | 2002-05-04 | 2018-05-01 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
US9468671B2 (en) | 2002-05-04 | 2016-10-18 | Acorda Therapeutics, Inc. | Compositions and methods for promoting neuronal outgrowth |
US9528102B2 (en) | 2003-05-16 | 2016-12-27 | Acorda Therapeutics, Inc. | Proteoglycan degrading mutants for treatment of CNS |
US8679481B2 (en) | 2003-05-16 | 2014-03-25 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
US8906363B2 (en) | 2003-05-16 | 2014-12-09 | Acorda Therapeutics, Inc. | Fusion proteins for the treatment of CNS |
US11141467B2 (en) | 2003-05-16 | 2021-10-12 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
US9839679B2 (en) | 2003-05-16 | 2017-12-12 | Acorda Therapeutics, Inc. | Methods of reducing extravasation of inflammatory cells |
US9834764B2 (en) | 2005-09-26 | 2017-12-05 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US9402886B2 (en) | 2005-09-26 | 2016-08-02 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US10323240B2 (en) | 2005-09-26 | 2019-06-18 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US9410141B2 (en) | 2006-10-10 | 2016-08-09 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US9987340B2 (en) | 2006-10-10 | 2018-06-05 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
US9102930B2 (en) | 2006-10-10 | 2015-08-11 | Acorda Therapeutics, Inc. | Compositions and methods of using chondroitinase ABCI mutants |
WO2010100247A1 (en) | 2009-03-06 | 2010-09-10 | Novartis Forschungsstiftung, Zweigniederlassung, Friedrich Miescher Institute For Biomedical Research | Novel therapy for anxiety |
Also Published As
Publication number | Publication date |
---|---|
CA3086902C (en) | 2021-11-09 |
CA3009034A1 (en) | 2008-04-17 |
EP2450442A1 (en) | 2012-05-09 |
AU2007307736A1 (en) | 2008-04-17 |
AU2007307736A2 (en) | 2009-11-26 |
WO2008045970A9 (en) | 2013-06-20 |
US8404232B2 (en) | 2013-03-26 |
AU2007307736C1 (en) | 2014-04-10 |
JP5391069B2 (en) | 2014-01-15 |
US20150322422A1 (en) | 2015-11-12 |
US20130210082A1 (en) | 2013-08-15 |
AU2007307736B2 (en) | 2013-10-03 |
US7722864B2 (en) | 2010-05-25 |
US9410141B2 (en) | 2016-08-09 |
EP2079835B1 (en) | 2014-03-26 |
ES2642088T3 (en) | 2017-11-15 |
JP2010505448A (en) | 2010-02-25 |
CA3086902A1 (en) | 2008-04-17 |
EP2079835A4 (en) | 2009-12-09 |
CA3009034C (en) | 2020-08-18 |
US20090060895A1 (en) | 2009-03-05 |
US9102930B2 (en) | 2015-08-11 |
US20170028038A1 (en) | 2017-02-02 |
WO2008045970A8 (en) | 2012-11-29 |
CA2666536C (en) | 2018-08-07 |
EP2450442B1 (en) | 2017-07-19 |
US9987340B2 (en) | 2018-06-05 |
CA2666536A1 (en) | 2008-04-17 |
WO2008045970A3 (en) | 2008-11-27 |
EP2079835A2 (en) | 2009-07-22 |
US20110014158A1 (en) | 2011-01-20 |
ES2473610T3 (en) | 2014-07-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9987340B2 (en) | Compositions and methods of using chondroitinase ABCI mutants | |
US9834764B2 (en) | Compositions and methods of using chondroitinase ABCI mutants | |
AU2016206267B2 (en) | Compositions and methods of using chondroitinase abci mutants | |
AU2014200000B2 (en) | Compositions and methods of using chondroitinase abci mutants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07853916 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2666536 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2009532566 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007307736 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007853916 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2007307736 Country of ref document: AU Date of ref document: 20071010 Kind code of ref document: A |